Monday, April 18, 2011
Halozyme Therapeutics Inc., of San Diego, said results in a Type I diabetes study of patients who receive their insulin treatment via pump demonstrated that Aspart-PH20, a formulation of the company's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog (aspart, Novo Nordisk A/S), accelerated insulin absorption and shortened its duration of action. Data were presented at the American Association of Clinical Endocrinologists meeting in San Diego.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.